Chuck Royce's CORT Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 166,562 shares of Corcept Therapeutics Incorporated (CORT) worth $5.8 M, representing 0.06% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in CORT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 227,477 shares. Largest reduction occurred in Q1 2025, reducing 148,986 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1,997 | Reduce 1.18% | 166,562 | $34.80 |
| Q2 2025 | -20,755 | Reduce 10.96% | 168,559 | $73.40 |
| Q1 2025 | -148,986 | Reduce 44.04% | 189,314 | $114.22 |
| Q4 2024 | -24,972 | Reduce 6.87% | 338,300 | $50.39 |
| Q3 2024 | +13,000 | Add 3.71% | 363,272 | $46.28 |
| Q2 2024 | +14,000 | Add 4.16% | 350,272 | $32.49 |
| Q1 2024 | +197 | Add 0.06% | 336,272 | $25.19 |
| Q4 2023 | -17,029 | Reduce 4.82% | 336,075 | $32.48 |
| Q3 2023 | +59,363 | Add 20.21% | 353,104 | $27.24 |
| Q2 2023 | -12,513 | Reduce 4.09% | 293,741 | $22.25 |
| Q1 2023 | +46,780 | Add 18.03% | 306,254 | $21.66 |
| Q4 2022 | -13,239 | Reduce 4.85% | 259,474 | $20.31 |
| Q3 2022 | -7,737 | Reduce 2.76% | 272,713 | $25.64 |
| Q2 2022 | +69 | Add 0.02% | 280,450 | $23.78 |
| Q1 2022 | +227,477 | Add 429.98% | 280,381 | $22.52 |
| Q4 2021 | +3,041 | Add 6.10% | 52,904 | $19.79 |
| Q3 2021 | -2,310 | Reduce 4.43% | 49,863 | $19.67 |
| Q2 2021 | -270 | Reduce 0.51% | 52,173 | $22.00 |
| Q1 2021 | -8,760 | Reduce 14.31% | 52,443 | $23.80 |
| Q4 2020 | -1,503 | Reduce 2.40% | 61,203 | $26.16 |
| Q3 2020 | -570 | Reduce 0.90% | 62,706 | $17.40 |
| Q2 2020 | -2,165 | Reduce 3.31% | 63,276 | $16.82 |
| Q1 2020 | -1,271 | Reduce 1.91% | 65,441 | $11.89 |
| Q4 2019 | +6,915 | Add 11.56% | 66,712 | $12.10 |
| Q3 2019 | +20,298 | Add 51.39% | 59,797 | $14.13 |
| Q2 2019 | +17,093 | Add 76.29% | 39,499 | $11.14 |
| Q1 2019 | +21,159 | Add 1696.79% | 22,406 | $11.74 |
| Q4 2018 | -371 | Reduce 22.93% | 1,247 | $13.63 |
| Q3 2018 | +871 | Add 116.60% | 1,618 | $14.22 |
| Q2 2018 | +747 | New Buy | 747 | $16.06 |
Chuck Royce's Corcept Therapeutics Incorporated Investment FAQs
Chuck Royce first purchased Corcept Therapeutics Incorporated (CORT) in Q2 2018, acquiring 747 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Corcept Therapeutics Incorporated (CORT) for 31 quarters since Q2 2018.
Chuck Royce's largest addition to Corcept Therapeutics Incorporated (CORT) was in Q1 2022, adding 280,381 shares worth $6.31 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 166,562 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $5.8 M.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.06% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Corcept Therapeutics Incorporated (CORT) was 363,272 shares, as reported at the end of Q3 2024.